In vitro induction and selection of fluoroquinolone-resistant mutants of Streptococcus pyogenes strains with multiple emm types

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 1, 2007, Pages 28-34

  Billal, Dewan S ^a   Fedorko, Daniel P ^b   Yan, S Steve ^c   Hotomi, Muneki ^a   Fujihara, Keiji ^a   Nelson, Nancy ^b   Yamanaka, Noboru ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Laboratory induction and selection; Point mutations; Resistance; S. pyogenes

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; GATIFLOXACIN; LEVOFLOXACIN; NORFLOXACIN; OFLOXACIN; PROTEIN PARC; PROTEIN PARE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERINE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENETICS; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM MUTANT; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENETIC POLYMORPHISM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POINT MUTATION; STRAIN DIFFERENCE; STREPTOCOCCUS PYOGENES;

ANTI-INFECTIVE AGENTS; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; POINT MUTATION; STREPTOCOCCUS PYOGENES;

EID: 33845875160     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl428     Document Type: Article

References (22)

1. Yan SS, Fox ML, Holland SM et al. Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes: identification of gyrA and parC and specification of point mutations associated with resistance. Antimicrob Agents Chemother 2000; 44: 3196-8.
2. Richter SS, Diekema DJ, Heilmann KP et al. Fluoroquinolone resistance in Streptococcus pyogenes. Clin Infect Dis 2003; 36: 380-3.
3. Reinert RR, Lutticken R, Al-Lahham A. High-level fluoroquinolone resistance in a clinical Streptoccoccus pyogenes isolate in Germany. Clin Microbiol Infect 2004; 10: 659-62.
4. Orscheln RC, Johnson DR, Olson SM et al. Intrinsic reduced susceptibility of serotype 6 Streptococcus pyogenes to fluoroquinolone antibiotics. J Infect Dis 2005; 191: 1272-9.
5. Perez-Trallero E, Fernandez-Mazarrasa C, Garcia-Rey C et al. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: Results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001; 45: 3334-40.
6. Alonso R, Galimand M, Courvalin P. parC mutation conferring ciprofloxacin resistance in Streptococcus pyogenes BM4513. Antimicrob Agents Chemother 2002; 46: 3686-7.
7. Malhotra-Kumar S, Lammens C, Chapelle S et al. Clonal spread of fluoroquinolone non-susceptible Streptococcus pyogenes. J Antimicrob Chemother 2005; 55: 320-5.
8. Gootz TD, Zaniewski R, Haskell S et al. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob Agents Chemother 1996; 40: 2691-7.
9. MacGowan AP, Bowker KE, Wootton M et al. Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and streptococci of Lancefield Groups A and G. J Antimicrob Chemother 1999; 44: 761-6.
10. Boos M, Mayer S, Fischer A et al. In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus. Antimicrob Agents Chemother 2001; 45: 938-42.
11. Schmitz FJ, Boos M, Mayer S et al. In vitro activities of novel des-fluoro(6) quinolone BMS-284756 against mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus selected with different quinolones. Antimicrob Agents Chemother 2002; 46: 934-5.
12. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Sixth Edition: Approved Standard M7-A6. NCCLS, Villanova, PA, USA, 2003.
13. Alonso R, Mateo E, Galimand M et al. Clonal spread of pediatric isolates of ciprofloxacin-resistant, emm type 6 Streptococcus pyogenes. J Clin Microbiol 2005; 43: 2492-3.
14. Powis J, McGeer A, Duncan C et al. Prevalence and characterization of invasive isolates of Streptococcus pyogenes with reduced susceptibility to fluoroquinolones. Antimicrob Agents Chemother 2005; 49: 2130-2.
15. Rivera A, Rebollo M, Sanchez F et al. Characterization of fluoroquinolone-resistant clinical isolates of Streptococcus pyogenes in Barcelona, Spain. Clin Microbiol Infect 2005; 11: 759-61.
16. Tankovic J, Perichon B, Duval J et al. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob Agents Chemother 1996; 40: 2505-10.
17. Pan XS, Ambler J, Mehtar S et al. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 1996; 40: 2321-6.
18. Alberti S, Garcia-Rey C, Dominguez MA et al. Survey of emm gene sequences from pharyngeal Streptococcus pyogenes isolates collected in Spain and their relationship with erythromycin susceptibility. J Clin Microbiol 2003; 41: 2385-90.
19. Zheng X, Johnson C, Lu Y et al. Clinical isolates of Streptococcus pneumoniae resistant to levofloxacin contain mutations in both gyrA and parC genes. Int J Antimicrob Agents 2001; 18: 373-8.
20. Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis 2002; 2: 530-8.
21. Weigel LM, Anderson GJ, Facklam RR et al. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45: 3517-23.
22. Montanari MP, Tili E, Cochetti I et al. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy. Microb Drug Resist 2004; 10: 209-17.